Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 7 member 3 (SLC7A3) is a sodium-independent cationic amino acid transporter that belongs to the CAT subfamily of the SLC7 family[1]. The protein serves as a uniporter that mediates the uptake of cationic L-amino acids, particularly L-arginine, L-lysine, and L-ornithine[3]. SLC7A3 is encoded by a gene located on chromosome Xq13.1 and produces a 619-amino acid protein with 14 transmembrane domains[2]. The transporter plays a crucial role in neuronal function, with selective expression in the brain[5]. It facilitates the transport of essential amino acids through passive diffusion in a sodium-independent and pH-independent manner[3]. The protein is moderately trans-stimulated and does not require energy coupling for its transport function[3]. SLC7A3 has significant importance in neuronal development and plasticity through its regulation of arginine availability, which affects the mammalian target of rapamycin (mTOR) signaling pathway[2][5]. The transporter responds to NMDA receptor activation and helps control cellular processes critical for brain function[5]. Arginine transported by SLC7A3 serves as a precursor for nitric oxide synthesis, creatine production, and polyamine synthesis through ornithine[5]. Clinical significance includes associations with autism spectrum disorders, where rare hypomorphic variants in SLC7A3 have been identified in male patients[4][5]. Functional studies have shown that certain missense variants can cause severe or moderate loss of CAT-3 function due to altered protein stability or abnormal trafficking to the plasma membrane[5]. The gene is highly intolerant to variation in humans, as evidenced by the low frequency of deleterious variants in population databases[5].
Cationic amino acid transport, Arginine uptake facilitation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 7 member 3 (SLC7A3).